Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




POC Blood Test Could Diagnose Brain Tumors Earlier

By LabMedica International staff writers
Posted on 04 Aug 2022

New research could lead to the development of a simple blood test for glioblastomas (GBMs), resulting in earlier diagnosis and more effective and personalized treatment options for the most common type of malignant brain cancer. More...

The research involves the development of mathematical models to assess the current use of biomarkers in the detection of GBMs and how such biomarker-based strategies can be improved.

This research is part of a wider CRUX project led by the University of Bristol (Bristol, UK) to develop an affordable, point of care blood test to diagnose brain tumors. This cross-disciplinary project combines biomarker discovery, development of fluorescent nanoparticle and new testing techniques with computational modeling. In their recent study, mathematical models were developed and paired with experimental data. The researchers found that for the prospective GBM biomarker Glial fibrillary acidic protein (GFAP) lowering the current biomarker threshold could lead to earlier detection of GBMs. The team also used computational modeling to explore the impact of tumor characteristics and patient differences on detection and strategies for improvements.

“Our findings provide the basis for further clinical data on the impact of lowering the current detection threshold for the known biomarker, GFAP, to allow earlier detection of GBMs using blood tests,” said Dr. Johanna Blee, lead author and Research Associate in the University of Bristol’s Department of Engineering Mathematics. “With further experimental data, it may also be possible to quantify tumor and patient heterogeneities and incorporate errors into our models and predictions for blood levels for different tumors. We have also demonstrated how our models can be combined with other diagnostics such as scans to enhance clinical insight with a view to developing more personalized and effective treatments.”

“These mathematical models could be used to examine and compare new biomarkers and tests for brain tumors as they emerge. We are hopeful this research will ultimately aid the development of a simple blood test for brain tumors, enabling earlier and more detailed diagnoses,” added Dr. Blee.

Related Links:
University of Bristol 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.